Cargando…

IDH1/2 mutations in acute myeloid leukemia

The mutational and epigenetic landscape of acute myeloid leukemia (AML) has become increasingly well understood in recent years, informing on biological targets for precision medicine. Among the most notable findings was the recognition of mutational hot-spots in the isocitrate dehydrogenase (IDH) g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Byun, Ja Min, Yoo, Seung-Joo, Kim, Hyeong-Joon, Ahn, Jae-Sook, Koh, Youngil, Jang, Jun Ho, Yoon, Sung-Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958365/ https://www.ncbi.nlm.nih.gov/pubmed/35197370 http://dx.doi.org/10.5045/br.2021.2021152

Ejemplares similares

Leukemic stem cell phenotype is associated with mutational profile in acute myeloid leukemia
por: Han, Heejoo, et al.
Publicado: (2021)

Concomitant ruxolitinib with cytarabine-based induction chemotherapy in secondary acute myeloid leukemia evolving from myeloproliferative neoplasm
por: Kim, Dong Hyun, et al.
Publicado: (2023)

Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm
por: Issa, Ghayas C., et al.
Publicado: (2021)

Effects of Somatic Mutations Are Associated with SNP in the Progression of Individual Acute Myeloid Leukemia Patient: The Two-Hit Theory Explains Inherited Predisposition to Pathogenesis
por: Park, Soyoung, et al.
Publicado: (2013)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions
por: Wouters, Bas J.
Publicado: (2021)

Highly Sensitive Detection of IDH2 Mutations in Acute Myeloid Leukemia
por: Petiti, Jessica, et al.
Publicado: (2020)

Should patients receive consolidation chemotherapy before reduced intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission?
por: Byun, Ja Min, et al.
Publicado: (2021)

Identification of somatic mutations using whole-exome sequencing in Korean patients with acute myeloid leukemia
por: Heo, Seong Gu, et al.
Publicado: (2017)

Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies
por: Lee, Eunyoung, et al.
Publicado: (2021)

Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas
por: Park, Chul-Kee, et al.
Publicado: (2015)

FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs
por: Ahn, Jae-Sook, et al.
Publicado: (2022)

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
por: Wang, Feng, et al.
Publicado: (2021)

PB1859: DNMT3A MUTATION PATTERNS AND CLINICAL FEATURES IN KOREAN ACUTE MYELOID LEUKEMIA PATIENTS
por: Lee, Eunyoung, et al.
Publicado: (2023)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

Metabolic Profiling during Acute Myeloid Leukemia Progression Using Paired Clinical Bone Marrow Serum Samples
por: Kim, Hyun Kyu, et al.
Publicado: (2021)

The Frequency and Clinical Significance of IDH1 Mutations in Chinese Acute Myeloid Leukemia Patients
por: Guan, Lixun, et al.
Publicado: (2013)

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
por: Gupta, Charu, et al.
Publicado: (2020)

Concurrent inhibition of IDH and methyltransferase maximizes therapeutic efficacy in IDH mutant acute myeloid leukemia
por: Zeng, Zhihong, et al.
Publicado: (2021)

Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro
por: Sarkaria, Shawn M., et al.
Publicado: (2014)

Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis
por: Chen, Xiu, et al.
Publicado: (2023)

Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia
por: Ahn, Seo-Yeon, et al.
Publicado: (2023)

High Frequency of ASXL1 and IDH Mutations in Young Acute Myeloid Leukemia Egyptian Patients
por: El Nahass, Yasser H, et al.
Publicado: (2022)

Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Merchant, Shelby L., et al.
Publicado: (2019)

The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid Leukemia
por: Zhuang, Xiaomei, et al.
Publicado: (2022)

Transcriptional signatures of the BCL2 family for individualized acute myeloid leukaemia treatment
por: Lee, Chansub, et al.
Publicado: (2022)

Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype
por: Ahn, Jae-Sook, et al.
Publicado: (2017)

RTK-RAS pathway mutation is enriched in myeloid sarcoma
por: Choi, Mihong, et al.
Publicado: (2018)

Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
por: Ok, Chi Young, et al.
Publicado: (2019)

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
por: Pollyea, Daniel A., et al.
Publicado: (2022)

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol
por: Messina, Monica, et al.
Publicado: (2022)

Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations
por: Daido, Yusuke, et al.
Publicado: (2023)

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia
por: Chaturvedi, Anuhar, et al.
Publicado: (2020)

5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia
por: Ahn, Jae-Sook, et al.
Publicado: (2016)

Distinctive patterns of peripheral neuropathy across the spectrum of plasma cell disorders
por: Byun, Ja Min, et al.
Publicado: (2019)

Optimizing Preparative Regimen for Umbilical Cord Blood Transplantation in Adult Acute Leukemia Patients: Acute Lymphoblastic Leukemia Requires Myeloablative Conditioning but Not Acute Myeloid Leukemia
por: Byun, Ja Min, et al.
Publicado: (2020)

Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Myers, Rebecca A., et al.
Publicado: (2018)

Minor BCR-ABL1-Positive Acute Myeloid Leukemia Associated With the NPM1 Mutation and FLT3 Internal Tandem Duplication
por: Kim, Moon Jung, et al.
Publicado: (2016)

Novel Multiplex Bead-Based Assay for Detection of IDH1 and IDH2 Mutations in Myeloid Malignancies
por: Shivarov, Velizar, et al.
Publicado: (2013)

CLINICAL AND BIOLOGICAL IMPLICATIONS OF ANCESTRAL AND NON-ANCESTRAL IDH1 AND IDH2 MUTATIONS IN MYELOID NEOPLASMS
por: Molenaar, Remco J., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cusns8uqdgeh3smgu15ok9da79